HER-2 Binding Antibodies

ABSTRACT

The present invention relates to monoclonal antibodies that specifically bind to HER2, or a fragment or derivative thereof or a polypeptide that contains at least a portion of said antibody that is sufficient to confer specific HER2 binding to the polypeptide. Said antibodies bind to the human Fc receptor and induce FcR mediated signaling pathways. The antibodies according to the invention bind to a different epitope than trastuzumab. 
     The invention also relates to the use of an antibody according to the invention in the treatment of a HER-2 mediated disease. 
     The present invention also relates to a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of the antibody according to the invention, and the use of said composition in the treatment of a HER-2 mediated disease.

CROSS REFERENCE TO RELATED APPLICATIONS

This application is a continuation of U.S. application Ser. No.16/099,228 filed on Nov. 6, 2018, which claims the priority benefit ofPCT/EP2017/060935 filed on May 8, 2017 which claims priority benefit ofEuropean Application No. 16168619.1 filed May 6, 2016. The entirecontents of which are hereby incorporated by reference herein.

SEQUENCE LISTING

The instant application contains a Sequence Listing which has beensubmitted electronically in ASCII format and is hereby incorporated byreference in its entirety. Said ASCII copy, created on Oct. 25, 2018, isnamed 18744_0121_SL.txt and is 47,653 bytes in size.

FIELD OF INVENTION

The present invention relates to monoclonal antibodies that specificallybind to HER2, or a fragment or derivative thereof or a polypeptide thatcontains at least a portion of said antibody that is sufficient toconfer specific HER2 binding to the polypeptide. The invention alsorelates to methods of using said antibodies and compositions comprisingthem in the diagnosis, prognosis and therapy of diseases such as cancer,autoimmune diseases, inflammatory disorders, and infectious diseases.

BACKGROUND

Receptor tyrosine-protein kinase erbB-2, also known as CD340 (cluster ofdifferentiation 340), proto-oncogene Neu, Erbb2 (rodent), or ERBB2(human) is a protein that in humans is encoded by the ERBB2 gene, whichis also frequently called HER2 (from human epidermal growth factorreceptor 2) or HER2/neu.

HER2 is a member of the human epidermal growth factor receptor(HER/EGFR/ERBB) family. HER2, a known proto-oncogene, is located at thelong arm of human chromosome 17 (17q12). Amplification or overexpressionof this oncogene has been shown to play an important role in thedevelopment and progression of certain aggressive types of breastcancer. In recent years, the protein has become an important biomarkerand target of therapy for approximately 30% of breast cancer patients.

The ErbB family consists of four plasma membrane-bound receptor tyrosinekinases. One of which is erbB-2, and the other members being epidermalgrowth factor receptor, erbB-3 (neuregulin-binding; lacks kinasedomain), and erbB-4. All four contain an extracellular ligand bindingdomain, a transmembrane domain, and an intracellular domain that caninteract with a multitude of signaling molecules and exhibit bothligand-dependent and ligand-independent activity. HER2 canheterodimerise with any of the other three receptors and is consideredto be the preferred dimerisation partner of the other ErbB receptors.

Dimerisation results in the autophosphorylation of tyrosine residueswithin the cytoplasmic domain of the receptors and initiates a varietyof signaling pathways. These include the mitogen-activated proteinkinase (MAPK) pathway, the phosphoinositide 3-kinase (PI3K/Akt) pathway,phospholipase C γ-, protein kinase C (PKC)-, and the Signal transducerand activator of transcription (STAT) pathways. Therefore, signalingthrough the ErbB family of receptors promotes cell proliferation andopposes apoptosis, and consequently must be tightly regulated to preventuncontrolled cell growth from occurring.

Amplification or over-expression of the ERBB2 gene occurs inapproximately 15-30% of breast cancers. It is strongly associated withincreased disease recurrence and a poor prognosis. Over-expression isalso known to occur in ovarian, stomach, and aggressive forms of uterinecancer, such as uterine serous endometrial carcinoma. For example, HER-2is overexpressed in approximately 7-34% of patients with gastric cancerand in 30% of salivary duct carcinomas.

Diverse structural alterations have been identified that causeligand-independent firing of this receptor, doing so in the absence ofreceptor over-expression.

HER2 is found in a variety of tumors and some of these tumors carrypoint mutations in the sequence specifying the transmembrane domain ofHER2. Substitution of a valine for a glutamic acid in the transmembranedomain can result in the constitutive dimerization of this protein inthe absence of a ligand. HER2 mutations have also been found innon-small-cell lung cancers (NSCLC) and can direct treatment.

HER2 is the target of the monoclonal antibody trastuzumab (marketed asHerceptin). Trastuzumab is effective only in cancers where HER2 isover-expressed. One year of trastuzumab therapy is recommended for allpatients with HER2-positive breast cancer who are also receivingchemotherapy. An important downstream effect of trastuzumab binding toHER2 is an increase in p27, a protein that halts cell proliferation.

Another monoclonal antibody, pertuzumab, which inhibits dimerization ofHER2 and HER3 receptors, was approved by the FDA for use in combinationwith trastuzumab in June 2012.

Additionally, NeuVax (Galena Biopharma) is a peptide-based immunotherapythat directs “killer” T cells to target and destroy cancer cells thatexpress HER2. It has entered phase 3 clinical trials.

HER2 testing is performed in breast cancer patients to assess prognosisand to determine suitability for trastuzumab therapy. It is importantthat trastuzumab is restricted to HER2-positive individuals as it isexpensive and has been associated with cardiac toxicity. ForHER2-negative tumors, the risks of trastuzumab clearly outweigh thebenefits.

Thus, there is a need for the development of novel, more effectiveantibodies that can be used in follow-up therapies when results of thegold-standard therapy with trastuzumab (and chemotherapy) are notsatisfying or as an alternative in combination with existing antibodies.

Aim of the study underlying the present invention was to generate alarge quantity of high-affinity antibodies against HER2 in order to findnew molecules with a novel mechanism of action in comparison to existingantibodies and therapies, such as trastuzumab and pertuzumab.

SUMMARY OF INVENTION

The present invention relates to a monoclonal antibody that specificallybinds to HER2, or a fragment or derivative thereof or a polypeptide thatcontains at least a portion of said antibody that is sufficient toconfer specific HER2 binding to the polypeptide, wherein said antibodybinds to the human Fc receptor and induces FcR mediated signalingpathways. In some embodiments, the antibody according to the inventionbinds to a different epitope as trastuzumab.

The invention also relates to a method of treating an HER-2 mediateddisease in a patient, comprising administering to a patient apharmaceutically effective amount of the antibody according to theinvention.

The present invention further relates to a pharmaceutical compositioncomprising a pharmaceutically acceptable carrier and a therapeuticallyeffective amount of the antibody according to the invention. Saidpharmaceutical composition can be administered to a patient in a methodof treating an HER-2 mediated disease according to the invention.

DEFINITIONS

The term “rabbit” according to the invention means an animal of themembers of the taxonomic order Lagomorpha, which includes the families(hares and rabbits) and Ochotonidae (pikas), preferably of genusOryctolagus.

The term “antibody” encompasses the various forms of antibody structuresincluding, but not being limited to, whole antibodies and antibodyfragments as long as it shows the properties according to the invention.

The term “rabbit monoclonal antibody “according to the invention means amonoclonal antibody produced by immunizing a rabbit and isolated from anantigen producing cell of said rabbit as well as such an antibody whichis further modified, preferably a humanized antibody, a chimericantibody, a fragment thereof, or a further genetically engineered andrecombinant produced antibody as long as the characteristic propertiesaccording to the invention are retained. Preferably the antibody is froma B cell or a rabbit hybridoma cell of said rabbit.

The term “antibody producing cell” according to the invention means arabbit B cell which produce antibodies, preferably a B cell or rabbithybridoma cell.

“Native antibodies” are usually heterotetrameric glycoproteins composedof two identical light (L) chains and two identical heavy (H) chains.Each light chain is linked to a heavy chain by one covalent disulfidebond, while the number of disulfide linkages varies among the heavychains of different immunoglobulin isotypes. Each heavy and light chainalso has regularly spaced intrachain disulfide bridges. Each heavy chainhas at one end a variable domain (VH) followed by a number of constantdomains. Each light chain has a variable domain at one end (VL) and aconstant domain at its other end. The constant domain of the light chainis aligned with the first constant domain of the heavy chain, and thelight-chain variable domain is aligned with the variable domain of theheavy chain. Particular amino acid residues are believed to form aninterface between the light chain and heavy chain variable domains.

“Percent (%) amino acid sequence identity” with respect to a peptide orpolypeptide sequence is defined as the percentage of amino acid residuesin a candidate sequence that are identical with the amino acid residuesin the specific peptide or polypeptide sequence, after aligning thesequences and introducing gaps, if necessary, to achieve the maximumpercent sequence identity, and not considering any conservativesubstitutions as part of the sequence identity. Alignment for purposesof determining percent amino acid sequence identity can be achieved invarious ways that are within the skill in the art, for instance, usingpublicly available computer software such as BLAST, BLAST-2, ALIGN orMegalign (DNASTAR) software.

The terms “Fc receptor” or “FcR” as used here refers to a human receptorthat binds to the Fc region of an antibody. FcRs bind IgG antibodies andinclude receptors of the FcγRI, FcγRII, and FcγRIII subclasses,including allelic variants and alternatively spliced forms of thesereceptors. FcγRII receptors include FcγRIIA (an “activating receptor”)and FcγRIIB (an “inhibiting receptor”), which have similar amino acidsequences that differ primarily in the cytoplasmic domains thereof.Activating receptor FcγRIIA contains an immunoreceptor tyrosine-basedactivation motif (ITAM) in its cytoplasmic domain. Inhibiting receptorFcγRIIB contains an immunoreceptor tyrosine-based inhibition motif(ITIM) in its cytoplasmic domain (see review M. in Daeron, Annu. Rev.Immunol. 15:203-234 (1997)). FcRIIIA (CD16a) mediaties ADCC. FcRs arereviewed in Ravetch and Kinet, Annu. Rev. Immunol 9:457-92 (1991); Capelet al, Immunomethods 4:25-34 (1994); and de Haas et al, J. Lab. CHn.Med. 126:330-41 (1995). These and all other FcRs are encompassed by theterm “FcR” herein. The term also includes the neonatal receptor, FcRn,which is responsible for the transfer of maternal IgGs to the fetus(Guyer et al, J. Immunol. 117:587 (1976) and Kim et al, J. Immunol.24:249 (1994)) and mediates slower catabolism, thus longer half-life.

The “constant domains (constant parts)” are not involved directly inbinding of an antibody to an antigen, but exhibit e.g. also effectorfunctions. The heavy chain constant region that corresponds to humanIgG1 is called γ1 chain. The heavy chain constant region that correspondto human IgG3 is called γ3 chain. Human constant y heavy chains aredescribed in detail by Kabat, E. A. et al., Sequences of Proteins ofImmunological Interest, 5th ed., Public Health Service, NationalInstitutes of Health, Bethesda, Md. (1991), and by Brueggemann, M., etal., J. Exp. Med. 166 (1987) 1351-1361; Love, T. W., et al., MethodsEnzymol. 178 (1989) 515-527. Constant domains of IgG1 or IgG3 type areglycosylated at Asn297. “Asn 297” according to the invention means aminoacid asparagine located at about position 297 in the Fc region; based onminor sequence variations of antibodies, Asn297 can also be located someamino acids (usually not more than +3 amino acids) upstream ordownstream.

The term “antibody effector function(s),” or “effector function” as usedherein refers to a function contributed by an Fc effector domain(s) ofan IgG (e.g., the Fc region of an immunoglobulin). Such function can beeffected by, for example, binding of an Fc effector domain(s) to an Fcreceptor on an immune cell with phagocytic or lytic activity or bybinding of an Fc effector domain(s) to components of the complementsystem. Typical effector functions are ADCC, ADCP and CDC. An “antibodyfragment” refers to a molecule other than an intact antibody thatcomprises a portion of an intact antibody that binds the antigen towhich the intact antibody binds. Examples of antibody fragments includebut are not limited to Fv, Fab, Fab′, Fab′-SH, F(ab′)2; diabodies;linear antibodies; single-chain antibody molecules (e.g. scFv); andmultispecific antibodies formed from antibody fragments.

An “antibody that binds to the same epitope” as a reference antibodyrefers to an antibody that blocks binding of the reference antibody toits antigen in a competition assay by 50% or more, and conversely, thereference antibody blocks binding of the antibody to its antigen in acompetition assay by 50% or more. An exemplary competition assay isprovided herein.

“Antibody-dependent cell-mediated cytotoxicity” and “ADCC” refer to acell-mediated reaction in which nonspecific cytotoxic cells that expressFcRs (e.g. Natural Killer (NK) cells, neutrophils, and macrophages)recognize bound antibody on a target cell and subsequently cause lysisof the target cell. The primary cells for mediating ADCC, NK cells,express FcyRIII only, whereas monocytes express FcyRI, FcyRII andFCYRIII FCR expression on hematopoietic cells is summarized in Table 3on page 464 of Ravetch, and Kinet, Annu. Rev. Immunol 9 (1991) 457-492.The term “Antibody-dependent cellular phagocytosis” and “ADCP” refer toa process by which antibody-coated cells are internalized, either inwhole or in part, by phagocytic immune cells (e.g., macrophages,neutrophils and dendritic cells) that bind to an immunoglobulin Fcregion.

C1q” is a polypeptide that includes a binding site for the Fc region ofan immunoglobulin. C1q together with two serine proteases, C1r and C1s,forms the complex C1, the first component of the complement dependentcytotoxicity (CDC) pathway. Human C1q can be purchased commerciallyfrom, e.g. Quidel, San Diego, Calif.

The “class” of an antibody refers to the type of constant domain orconstant region possessed by its heavy chain. There are five majorclasses of antibodies: IgA, IgD, IgE, IgG, and IgM, and several of thesemay be further divided into subclasses (isotypes), e.g., IgG₁, IgG₂,IgG₃, IgG₄, IgA₅, and IgA₂. The heavy chain constant domains thatcorrespond to the different classes of immunoglobulins are called a, δ,ε, γ, and μ, respectively.

An “effective amount” of an agent, e.g., a pharmaceutical formulation,refers to an amount effective, at dosages and for periods of timenecessary, to achieve the desired therapeutic or prophylactic result.

The term “Fc region” herein is used to define a C-terminal region of animmunoglobulin heavy chain that contains at least a portion of theconstant region. The term includes native sequence Fc regions andvariant Fc regions.

Unless otherwise specified herein, numbering of amino acid residues inthe Fc region or constant region is according to the EU numberingsystem, also called the EU index, as described in Kabat, et al.,Sequences of Proteins of Immunological Interest, 5th Ed. Public HealthService, National Institutes of Health, Bethesda, Md. (1991).

A “variant Fc region” comprises an amino acid sequence which differsfrom that of a “native” or “wildtype” sequence Fc region by virtue of atleast one “amino acid modification” as herein defined.

The term “Fc-variant” as used herein refers to a polypeptide comprisinga modification in the Fc domain. For all positions discussed in thepresent invention, numbering is according to the EU index. The EU indexor EU index as in Kabat or EU numbering scheme refers to the numberingof the EU antibody (Edelman, et al., Proc Natl Acad Sci USA 63 (1969)78-85, hereby entirely incorporated by reference.) The modification canbe an addition, deletion, or substitution. Substitutions can includenaturally occurring amino acids and non- naturally occurring aminoacids. Variants may comprise non-natural amino acids.

The term “Fc region-containing polypeptide” refers to a polypeptide,such as an antibody or immunoadhesin (see definitions below), whichcomprises an Fc region.

The terms “Fc receptor” or “FcR” are used to describe a receptor thatbinds to the Fc region of an antibody. A FcR which binds an IgG antibody(a gamma receptor) includes receptors of the FcyRI, FcyRII, and FcyRIIIsubclasses, including allelic variants and alternatively spliced formsof these receptors. FcyRII receptors include FcyRIIA (an “activatingreceptor”) and FcyRIIB (an “inhibiting receptor”), which have similaramino acid sequences that differ primarily in the cytoplasmic domainsthereof. Activating receptor FcyRIIA contains an immunoreceptortyrosine-based activation motif (ITAM) in its cytoplasmic domain.Inhibiting receptor FcyRIIB contains an immunoreceptor tyrosine-basedinhibition motif (ITIM) in its cytoplasmic domain, (see review inDaeron, M., Annu. Rev. Immunol. 15 (1997) 203-234). FcRs are reviewed inRavetch, and Kinet, Annu. Rev. Immunol 9 (1991) 457-492; Capel, et al.,Immunomethods 4 (1994) 25-34; and de Haas, et al., J. Lab. Clin. Med.126 (1995) 330-41. Other FcRs, including those to be identified in thefuture, are encompassed by the term “FcR” herein. The term also includesthe neonatal receptor, FcRn, which is responsible for the transfer ofmaternal IgGs to the fetus (Guyer, et al., J. Immunol. 117 (1976) 587and Kim, et al., J. Immunol. 24 (1994) 249).

By “IgG Fc ligand” as used herein is meant a molecule, preferably apolypeptide, from any organism that binds to the Fc region of an IgGantibody to form an Fc/Fc ligand complex. Fc ligands include but are notlimited to FcyRs, FcyRs, FcyRs, FcRn, C1q, C3, mannan binding lectin,mannose receptor, staphylococcal protein A, streptococcal protein G, andviral FcyR. Fc ligands also include Fc receptor homologs (FcRH), whichare a family of Fc receptors that are homologous to the FcyRs (Davis, etal., Immunological Reviews 190 (2002) 123-136, entirely incorporated byreference). Fc ligands may include undiscovered molecules that bind Fc.Particular IgG Fc ligands are FcRn and Fc gamma receptors. By “Fcligand” as used herein is meant a molecule, preferably a polypeptide,from any organism that binds to the Fc region of an antibody to form anFc/Fc ligand complex.

By “Fc gamma receptor”, “FcyR” or “FcgammaR” as used herein is meant anymember of the family of proteins that bind the IgG antibody Fc regionand is encoded by an FcyR gene. In humans this family includes but isnot limited to FcyRI (CD64), including isoforms FcyRIA, FcyRIB, andFcyRIC; FcyRII (CD32), including isoforms FcyRIIA (including allotypesH131 and R131), FcyRIIB (including FcyRIIB-1 and FcyRIIB-2), andFcyRIIc; and FcyRIII (CD 16), including isoforms FcyRIIIA (includingallotypes VI 58 and F158) and FcyRIIIb (including allotypes FcyRIIB-NA1and FcyRIIB-NA2) (Jefferis, et al., Immunol Lett 82(2002) 57-65,entirely incorporated by reference), as well as any undiscovered humanFcyRs or FcyR isoforms or allotypes. An FcyR may be from any organism,including but not limited to humans, mice, rats, rabbits, and monkeys.Mouse FcyRs include but are not limited to FcyRI (CD64), FcyRII (CD32),FcyRIII (CD 16), and FCYRIII-2 (CD 16-2), as well as any undiscoveredmouse FcyRs or FcyR isoforms or allotypes.

By “FcRn” or “neonatal Fc Receptor” as used herein is meant a proteinthat binds the IgG antibody Fc region and is encoded at least in part byan FcRn gene. The FcRn may be from any organism, including but notlimited to humans, mice, rats, rabbits, and monkeys. As is known in theart, the functional FcRn protein comprises two polypeptides, oftenreferred to as the heavy chain and light chain. The light chain isbeta-2-microglobulin and the heavy chain is encoded by the FcRn gene.Unless otherwise noted herein, FcRn or an FcRn protein refers to thecomplex of FcRn heavy chain with beta-2-microglobulin.

An “immunoconjugate” means an antibody conjugated to one or morecytotoxic agents, such as a chemotherapeutic agent, a drug, a growthinhibitory agent, a toxin, another antibody or a radioactive isotope.

“Antibody fragments” comprise a portion of a full-length antibody,preferably the variable regions thereof, or at least the antigen bindingsite thereof. Examples of antibody fragments include diabodies, Fabfragments, and single-chain antibody molecules. scFv antibodies are,e.g., described in Huston, J. S., Methods in Enzymol. 203 (1991) 46-88.

The terms “monoclonal antibody” or “monoclonal antibody composition” asused herein refer to a preparation of antibody molecules of a singleamino acid composition.

The term “humanized antibody” or “humanized version of an antibody”refers to antibodies for which both heavy and light chains are humanizedas a result of antibody engineering. A humanized chain is typically achain in which the V-region amino acid sequence has been changed sothat, analyzed as a whole, is closer in homology to a human germlinesequence than to the germline sequence of the species of origin.Humanization assessment is based on the resulting amino acid sequenceand not on the methodology per se.

The terms “specifically binding, against target, or anti-targetantibody”, as used herein, refer to binding of the antibody to therespective antigen (target) or antigen-expressing cell, measured byELISA, wherein said ELISA preferably comprises coating the respectiveantigen to a solid support, adding said antibody under conditions toallow the formation of an immune complex with the respective antigen orprotein, detecting said immune complex by measuring the Optical Densityvalues (OD) using a secondary antibody binding to an antibody accordingto the invention and using a peroxidase-mediated color development.

The term “antigen” according to the invention refers to the antigen usedfor immunization or a protein comprising said antigen as part of itsprotein sequence. For example, for immunization a fragment of theextracellular domain of a protein (e.g. the first 20 amino acids) can beused and for detection/assay and the like the extracellular domain ofthe protein or the full length protein can be used.

The term “specifically binding” or “specifically recognized” hereinmeans that an antibody exhibits appreciable affinity for an antigen and,preferably, does not exhibit significant cross-reactivity.

“Appreciable” binding affinity includes binding with an affinity of atleast 10⁻⁷M, specifically at least 10⁻⁸M, more specifically at least10⁻⁹M, or even yet more specifically at least 10⁻¹⁰M.

An antibody that “does not exhibit significant cross-reactivity” is onethat will not appreciably bind to an undesirable other protein. Specificbinding can be determined according to any art-recognized means fordetermining such binding, e.g. by competitive binding assays such asELISA.

All protein terms as used herein refers to the human proteins. If aprotein from another species is meant, this is explicitly mentioned.

The “variable region (or domain) of an antibody according to theinvention” (variable region of a light chain (VL), variable region of aheavy chain (VH)) as used herein denotes each of the pair of light andheavy chain regions which are involved directly in binding the antibodyto the antigen. The variable light and heavy chain regions have the samegeneral structure and each region comprises four framework (FR) regionswhose sequences are widely conserved, connected by three complementarydetermining regions, CDRs.

The term “antigen-binding portion of an antibody” when used herein referto the amino acid residues of an antibody which are responsible forantigen-binding. The antigen-binding portion of an antibody comprisespreferably amino acid residues from the “complementary determiningregions” or “CDRs”. The CDR sequences are defined according to Kabat etal, Sequences of Proteins of Immunological Interest, 5th Ed. PublicHealth Service, National Institutes of Health, Bethesda, Md. (1991).Using this numbering system, the actual linear amino acid sequence maycontain fewer or additional amino acids corresponding to a shorteningof, or insertion into, a FR or CDR of the variable region. For example,a heavy chain variable region may include a single amino acid insert(residue 52a according to Kabat) after residue 52 of H2 and insertedresidues (e.g. residues 82a, 82b, and 82c, etc. according to Kabat)after heavy chain FR residue 82. The Kabat numbering of residues may bedetermined for a given antibody by alignment at regions of homology ofthe sequence of the antibody with a “standard” Kabat numbered sequence.

The term “cancer” as used herein may be, for example, lung cancer,non-small cell lung (NSCL) cancer, bronchioloalviolar cell lung cancer,bone cancer, pancreatic cancer, skin cancer, cancer of the head or neck,cutaneous or intraocular melanoma, uterine cancer, ovarian cancer,rectal cancer, cancer of the anal region, stomach cancer, gastriccancer, colon cancer, breast cancer, uterine cancer, carcinoma of thefallopian tubes, carcinoma of the endometrium, carcinoma of the cervix,carcinoma of the vagina, carcinoma of the vulva, Hodgkin's Disease,cancer of the esophagus, cancer of the small intestine, cancer of theendocrine system, cancer of the thyroid gland, cancer of the parathyroidgland, cancer of the adrenal gland, sarcoma of soft tissue, cancer ofthe urethra, cancer of the penis, prostate cancer, cancer of thebladder, cancer of the kidney or ureter, renal cell carcinoma, carcinomaof the renal pelvis, mesothelioma, hepatocellular cancer, biliarycancer, neoplasms of the central nervous system (CNS), spinal axistumors, brain stem glioma, glioblastoma multiforme, astrocytomas,schwanomas, ependymonas, medulloblastomas, meningiomas, squamous cellcarcinomas, pituitary adenoma, lymphoma, lymphocytic leukemia, includingrefractory versions of any of the above cancers, or a combination of oneor more of the above cancers. Preferably such cancer is a breast cancer,colon cancer, lung cancer, or pancreatic cancer.

DETAILED DESCRIPTION OF INVENTION

The present invention originates from making use of the technologiesestablished by the inventors, which allow for the production of a largeamount of diverse molecules with different properties.

The inventors produced more than 40.000 supernatants of B-cells andtested them, out of which they identified more than 7.500 antibodies,which bind to HER-receptors mono- or oligospecific in ELISA assays.

The RNA and amino acid sequences of 564 molecules were determined, andrespective antibodies were cloned, expressed and purified, generatingabout 300 recombinant chimeric antibodies. This genetic modification andpurification of the antibodies allows for specific biochemical testingof defined amounts of antibody, thus appropriate quantitative evaluationand for consequently for in vivo use as unwanted immune defensereactions are minimized.

The recombinant monoclonal antibodies were tested and compared in vitroand in vivo. Surprisingly, several molecules were found that show atleast a 2-fold increase of FcγRIIIa mediated activity in JIMT-1 cells,i.e. a higher activation of the NFAT pathway than trastuzumab/Herceptin. Moreover, some of the antibodies were found to bind todifferent epitopes than the gold-standard antibodies, trastuzumab (TZ)and pertuzumab (PZ), for breast cancer therapy.

Therefore, the present invention relates to a monoclonal antibody thatspecifically binds to HER2, or a fragment or derivative thereof or apolypeptide that contains at least a portion of said antibody that issufficient to confer specific HER2 binding to the polypeptide,comprising:

-   a) a heavy chain variable region (VH) comprising CDR-H1, CDR-H2, and    CDR-H3,    -   wherein the CDR-H1 region comprises an amino acid sequence        selected from the group of SEQ ID NO: 13-18,    -   wherein the CDR-H2 region comprises an amino acid sequence        selected from the group of SEQ ID NO: 19-24,    -   and wherein the CDR-H3 region comprises an amino acid sequence        selected from the group of SEQ ID NO: 25-30; and-   b) a light chain variable region (VL) comprising CDR-L1, CDR-L2,    CDR-L3, and    -   wherein the CDR-L1 region comprises an amino acid sequence        selected from the group of SEQ ID NO: 31-36,    -   wherein the CDR-L2 region comprises an amino acid sequence        selected from the group of SEQ ID NO: 37-42,    -   and wherein the CDR-L3 region comprises an amino acid sequence        selected from the group of SEQ ID NO: 43-48.

Furthermore, the antibody according to the invention may comprise a

-   a) heavy chain variable region (VH) that comprises the framework    regions FR-H1, FR-H2, FR-H3, and FR-H4,    -   wherein FR-H1 region comprises an amino acid sequence selected        from the group of SEQ ID NO: 49-54,    -   wherein the FR-H2 region comprises an amino acid sequence        selected from the group of SEQ ID NO: 55-60,    -   wherein the FR-H3 region comprises an amino acid sequence        selected from the group of SEQ ID NO: 61-66; and    -   and wherein the FR-H4 region comprises an amino acid sequence        selected from the group of SEQ ID NO: 67-72;-   b) light chain variable region (VL) that comprises the framework    regions FR-L1, FR-L2, FR-L3, and FR-L4,    -   wherein the FR-L1 region comprises an amino acid sequence        selected from the group of SEQ ID NO: 73-78,    -   wherein the FR-L2 region comprises an amino acid sequence        selected from the group of SEQ ID NO: 79-84,    -   and wherein the FR-L3 region comprises an amino acid sequence        selected from the group of SEQ ID NO: 85-90 and    -   wherein the FR-L4 region comprises an amino acid sequence        selected from the group of SEQ ID NO: 91-96.

In one embodiment, the antibody according to the invention is amonoclonal IgG antibody.

Preferably, the antibody according to the invention is a monoclonal IgG1antibody.

The monoclonal antibody according to the invention is an antibody thatspecifically binds to HER2, or a fragment or derivative thereof or apolypeptide that contains at least a portion of said antibody that issufficient to confer HER2 binding specificity, comprising a heavy chainvariable (VH) region is at least 90% identical to a VH region selectedfrom the group consisting of VH regions of SEQ ID NO: 1 to 6 and SEQ IDNO: 100 to 101, and a light chain variable (VL) region that is at least90% identical to a VL region selected from the group consisting of VLregions of SEQ ID NO: 7 to 12 and SEQ ID NO 102 to 104.

In an antibody according to the invention, the heavy chain variable (VH)region can be at least 60% identical, preferably at least 70% identical,more preferably at least 80% identical to a VH region selected from thegroup consisting of VH regions of SEQ ID NO: 1 to 6 and SEQ ID NO: 100to 101.

In one embodiment, the antibody according to the invention comprises aheavy chain variable region (VH) sequence having at least 80%, 81%, 82%,83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%,97%, 98%, 99%, or 100% sequence identity to an amino acid sequenceselected from the group of VH sequences according to the invention, i.e.SEQ ID NO: 1 to 6 and SEQ ID NO: 100 to 101.

Preferably, the antibody comprises a heavy chain variable (VH) regionthat is at least 90% identical to the VH region of SEQ ID NO: 4,preferably the VH region is 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%,or 100% identical to SEQ ID NO: 4, and most preferred the VH regioncomprises SEQ ID NO: 4.

In certain embodiments, a VH sequence having at least 80%, 81%, 82%,83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%,97%, 98%, or 99% identity contains substitutions (e.g., conservativesubstitutions), insertions, or deletions relative to the referencesequence, whereby the antibody retains the ability to bind specificallyaccording to the invention to the respective antigen. In certainembodiments, a total of 1 to 10 amino acids have been substituted,inserted and/or deleted in each of said VH sequences. In certainembodiments, substitutions, insertions, or deletions occur in regionsoutside the CDRs (i.e., in the FRs).

In a preferred embodiment, the heavy chain variable region (VH) sequenceis selected from the group consisting of VH regions of SEQ ID NO: 1 to 6and SEQ ID NO: 100 to 101.

Even more preferred, the heavy chain variable region (VH) sequence isSEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ IDNO:6, SEQ ID NO: 100 or 101. Most preferred, the VH sequence is SEQ IDNO:4.

In an antibody according to the invention, the light chain variable (VL)region can be at least 60% identical, preferably at least 70% identical,more preferably at least 80% identical to a VL region selected from thegroup consisting of VL regions of SEQ ID NO: 7 to 12 and SEQ ID NO 102to 104.

In one embodiment, the antibody according to the invention comprises alight chain variable region (VL) having at least 80%, 81%, 82%, 83%,84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%,98%, 99%, or 100% sequence identity to the amino acid sequence of the VLsequences according to the invention.

Preferably, the antibody comprises a light chain variable (VL) regionthat is at least 90% identical to the VL region of SEQ ID NO: 10,preferably 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%identical, and most preferred the VL region comprises SEQ ID NO: 10.

In some embodiments, a VL sequence having at least 80%, 81%, 82%, 83%,84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%,98%, or 99%o identity contains substitutions (e.g., conservativesubstitutions), insertions, or deletions relative to the referencesequence, whereby the antibody retains the ability to bind specificallyto the respective antigen. In certain embodiments, a total of 1 to 10amino acids have been substituted, inserted and/or deleted in said VLsequences. In certain embodiments, the substitutions, insertions, ordeletions occur in regions outside the CDRs (i.e., in the FRs).

In a preferred embodiment, the light chain variable region (VL) sequenceis selected from the group consisting of VL regions of SEQ ID NO: 7 to12 and SEQ ID NO 102 to 104.

Even more preferred, the heavy chain variable region (VL) sequence isSEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQID NO:12, SEQ ID NO 102, SEQ ID NO 103 or 104.

Most preferred, the VL sequence is SEQ ID NO:10.

Further preferred is that the VL sequences according to the inventioncomprise a mutation at position 90. Preferably, the VL sequencescomprising a sequence from the group of SEQ ID NO: 10, 102, 103 and 104,comprise a mutation at position 90. Preferably the mutation is aCysteine to Serine mutation. However, it can also be a different aminoacid substitution. The VL sequences may of course also comprise furthermutations as detailed above.

The invention also relates to an antibody, wherein its VH region is atleast 90% identical to a VH region of SEQ ID NO: 1+n and its VL regionis at least 90% identical to a VL region of SEQ ID NO: 7+n, wherein n isa number selected from the group consisting of 0 to 5.

The present invention also relates to an antibody, wherein the antibodycomprises a VH region selected from the group consisting of VH regionsof SEQ ID NO: 1+n and its VL region is selected from the groupconsisting of VL regions of SEQ ID NO: 7+n, wherein n is a numberselected from the group consisting of 0 to 5.

The present invention also relates to an antibody, wherein the antibodycomprises a VH region selected from the group of VH regions comprising aCDR-H1 region of SEQ ID NO: 13+n, a CDR-H2 region of SEQ ID NO: 19+n anda CDR-H3 region of SEQ ID NO: 25+n, wherein n is a number selected fromthe group consisting of 0 to 5.

Furthermore, an antibody according to the invention may comprise a VLregion selected from the group of VL regions comprising a CDR-L1 regionof SEQ ID NO: 31+n, a CDR-L2 region of SEQ ID NO: 37+n and a CDR-L3region of SEQ ID NO: 43+n, wherein n is a number selected from the groupconsisting of 0 to 5.

An antibody according to the invention may also comprise a VH regionselected from the group of VH regions comprising a CDR-H1 region of SEQID NO: 13+n, a CDR-H2 region of SEQ ID NO: 19+n and a CDR-H3 region ofSEQ ID NO: 25+n, and in that the antibody comprises a VL region selectedfrom the group of VL regions comprising a CDR-L1 region of SEQ ID NO:31+n, a CDR-L2 region of SEQ ID NO: 37+n and a CDR-L3 region of SEQ IDNO: 43+n, wherein n is a number selected from the group consisting of 0to 5.

“n is a number selected from the group of 0 to 5” according to theinvention means a number selected from the group of 0, 1, 2, 3, 4, and5. The number “n” according to the invention is meant to be identicalfor the same antibody, its heavy and light chains, its variable regionsand CDR regions.

Moreover, an antibody according to the present invention may comprise aVH region and a VL region comprising the respective CDR1, CDR2 and CDR3regions and the respective FR1, FR2, FR3, and FR4 regions of an antibodyselected from the group consisting of C074, C031, B106, B100, AK57,B115.

Preferably, the antibody comprises the VH region and VL regioncomprising the respective CDR1, CDR2 and CDR3 regions and the respectiveFR1, FR2, FR3, and FR4 regions of the antibody designated as B100(corresponding to MABD B100).

Preferably B100 is a humanized antibody.

Preferably, an antibody according to the invention comprises SEQ ID NO.:1 and 7. In another embodiment, an antibody according to the inventioncomprises SEQ ID NO.: 2 and 8. An antibody according to the inventionmay also comprise SEQ ID NO.: 3 and 9 or SEQ ID NO.: 4 and 10, or SEQ IDNO.: 5 and 11, or SEQ ID NO.: 6 and 12.

In a further preferred embodiment according to the invention, theantibody comprises SEQ ID NO.: 1, 7, and 98. In another embodiment, theantibody according to the invention comprises SEQ ID NO.: 2, 8, and 98.An antibody according to the invention may also comprise SEQ ID NO.: 3,9, and 98, or SEQ ID NO.: 4, 10, and 98, or SEQ ID NO.: 5, 11, and 99 orSEQ ID NO.: 6, 12, and 98.

In a further preferred embodiment according to the invention, theantibody comprises SEQ ID NO.: 1,7, and 97. In another embodiment, theantibody according to the invention comprises SEQ ID NO.: 2, 8, and 97.An antibody according to the invention may also comprise SEQ ID NO.: 3,9, and 97, or SEQ ID NO.: 4, 10, and 97, or SEQ ID NO.: 5, 11, and 97 orSEQ ID NO.: 6, 12, and 97.

In a further preferred embodiment according to the invention, theantibody comprises SEQ ID NO.: 1,7, 97 and 98. In another embodiment,the antibody according to the invention comprises SEQ ID NO.: 2, 8, 97and 98. An antibody according to the invention may also comprise SEQ IDNO.: 3, 9, 97 and 98, or SEQ ID NO.: 4, 10, 97 and 98, or SEQ ID NO.: 5,11, 97 and 99 or SEQ ID NO.: 6, 12, 97 and 98.

The present invention also relates to a monoclonal antibody thatspecifically binds to HER2, or a fragment or derivative thereof or apolypeptide that contains at least a portion of said antibody that issufficient to confer HER2 binding specificity, comprising:

-   a) a heavy chain variable region (VH) comprising FR-H1, CDR-H1,    FR-H2, CDR-H2, FR-H3, CDR-H3 and FR-H4    -   wherein the CDR-H1 region comprises an amino acid sequence        according to the formula:

(S/N)₁-(Y/S)₂-(N/A/G/Y)₃-(M/V/Y)₄-(G/A/S/M)₅-(0/C)₆

-   -   wherein the CDR-H2 region comprises an amino acid sequence        according to the formula:

(I/C)₁-(I)₂-(N/S/Y)₃-(H/A/S/G)₄-(G/I/S)₅-(D/G/S)₆-(N/T/F/D/S)₇-(T/A/N/S)₈-(Y/H/T/S)₉-(T/Y/W)₁₀-(F/A/Y)₁₁-(S/A/Y)₁₂-(W/A/S)₁₃-(W/A/S)₁₄-(K/A/W)₁₅-(G/A/K)₁₆-(0/G/K)₁₇-(0/AG)₁₈

-   -   and wherein the CDR-H3 region comprises an amino acid sequence        according to the formula:

(G/S/A/D)₁-(A/Y/D/V/L/Q)₂-(A/T/D/V/Y/I)₃-(P/A/S/G/Y)₄-(G/N/S/D)₅-(D/G/S/Y)₆-(G/T/N/L/S)₇-(R/A/G)₈-(Y/F/L/G)₉-(0/N/G/Y)₁₀-(0/I/Y/L)₁₁-(0/F)12-(0/S)13-(0/L)₁₄

-   b) a light chain variable region (VL) comprising FR-L1, CDR-L1,    FR-L2, CDR-L2, FR-L3, CDR-L3, and FR-L4    -   wherein the CDR-L1 region comprises an amino acid sequence        according to the formula:

(Q)₁-(A)₂-(S)₃-(Q)₄-(S)₅-(I)₆-(G/S/Y)₇-(T/N/S/I)₈-(Y/A/L)₉-(L)₁₀-(G/A/S)₁₁

-   -   wherein the CDR-L2 region comprises an amino acid sequence        according to the formula:

(G/Y/S/K)₁-(A)₂-(S)₃-(N/S/T)₄-(L)₅-(E/A)₆-(F/S)₇

-   -   and wherein the CDR-L3 region comprises an amino acid sequence        according to the formula:

(Q)₁-(C/N/S)₂-(S/T/N)₃-(A/D/N/Y)₄-(Y/V/A/G)₅-(G/S)₆-(G/S)₇-(R/N/V/Y/S)₈-(Y/S)₉-(V/S/L)₁₀-(G/A/W)₁₁-(G/A/T/F/E)₁₂-(0/G)₁₃-(0/A)₁₄

“0” herein indicates that there does not have to be an amino acid atthis position.

In one preferred embodiment, the antibody of the invention comprises aserine at position 2 of CDR-L3.

Most preferred, an antibody according to the invention comprises aCDR-H1 region comprising SEQ ID NO 16, a CDR-H2 region comprising SEQ IDNO: 22, a CDR-H3 region comprising SEQ ID NO: 28, and a CDR-L1 regioncomprising SEQ ID NO: 34. a CDR-L2 region comprising SEQ ID NO: 40, anda CDR-L3 region comprising SEQ ID NO: 46.

A monoclonal antibody according to the invention can be rabbit antibody.In a preferred embodiment, the antibody of the invention is arabbit/human chimeric antibody. In a further preferred version, theantibody is a humanized antibody.

Therefore, in a preferred embodiment, an antibody according to theinvention is a humanized antibody comprising a heavy chain variableregion (VH) comprising FR-H1, CDR-H1, FR-H2, CDR-H2, FR-H3, CDR-H3 andFR-H4 or a fragment or derivative thereof or a polypeptide that containsat least a portion of said antibody that is sufficient to confer HER2binding specificity, comprising:

-   a) a heavy chain variable region (VH) comprising FR-H1, CDR-H1,    FR-H2, CDR-H2, FR-H3, CDR-H3 and FR-H4    -   wherein the CDR-H1 region comprises an amino acid sequence        according to the formula:

(S/N)₁-(Y/S)₂-(N/A/G/Y)₃-(M/V/Y)₄-(G/A/S/M)₅-(0/C)₆

-   -   wherein the CDR-H2 region comprises an amino acid sequence        according to the formula:

(I/C)₁-(I)₂-(N/S/Y)₃-(H/A/S/G)₄-(G/1/S)₅-(D/G/S)₆-(N/T/F/D/S)₇-(T/A/N/S)₈-(Y/H/T/S)₉-(T/Y/W)₁₀-(F/A/Y)₁₁-(S/A/Y)₁₂-(W/A/S)₁₃-(W/A/S)₁₄-(K/A/W)₁₅-(G/A/K)₁₆-(0/G/K)₁₇-(0/AG)₁₈

-   -   and wherein the CDR-H3 region comprises an amino acid sequence        according to the formula:

(G/S/A/D)₁-(A/Y/D/V/L/Q)₂-(A/T/D/V/Y/I)₃-(P/A/S/G/Y)₄-(G/N/S/D)₅-(D/G/S/Y)₆-(G/T/N/L/S)₇-(R/A/G)₈-(Y/F/L/G)₉-(0/N/G/Y)₁₀-(0/I/Y/L)₁₁-(0/F)₁₂-(0/S)₁₃-(0/L)₁₄

-   b) a light chain variable region (VL) comprising FR-L1, CDR-L1,    FR-L2, CDR-L2, FR-L3, CDR-L3, and FR-L4    -   wherein the CDR-L1 region comprises an amino acid sequence        according to the formula:

(Q)₁-(A)₂-(S)₃-(Q)₄-(S)₅-(I)₆-(G/S/Y)₇-(T/N/S/I)₈-(Y/A/L)₉-(L)₁₀-(G/A/S)₁₁

-   -   wherein the CDR-L2 region comprises an amino acid sequence        according to the formula:

(G/Y/S/K)₁-(A)₂-(S)₃-(N/S/T)₄-(L)₅-(E/A)₆-(F/S)₇

-   -   and wherein the CDR-L3 region comprises an amino acid sequence        according to the formula:

(Q)₁-(C/N/S)₂-(S/T/N)₃-(A/D/N/Y)₄-(Y/V/A/G)₅-(G/S)₆-(G/S)₇-(R/N/V/Y/S)₈-(Y/S)₉-(V/S/L)₁₀-(G/A/W)₁₁-(G/A/T/F/E)₁₂-(0/G)₁₃-(0/A)₁₄

In one preferred embodiment, the antibody of the invention comprises aserine at position 2 of CDR-L3.

Preferably, an antibody according to the invention is a humanizedantibody comprising a CDR-H1 region comprising SEQ ID NO 16, a CDR-H2region comprising SEQ ID NO: 22, a CDR-H3 region comprising SEQ ID NO:28, and a CDR-L1 region comprising SEQ ID NO: 34. a CDR-L2 regioncomprising SEQ ID NO: 40, and a CDR-L3 region comprising SEQ ID NO: 46.

The present invention also encompasses an antibody that specificallybinds to HER2, or a fragment or derivative thereof or a polypeptide thatcontains at least a portion of said antibody that is sufficient toconfer HER2 binding specificity, wherein said antibody binds to thehuman Fc receptor and induces FcR mediated signaling pathways.

Preferably, the antibodies according to the invention show an increasedinduction of FcR mediated signaling pathway, when compared tocommercially available antibodies.

Surprisingly, the inventors identified several molecules that show atleast 50-fold increase (FoI: Fold of induction) of FcγRIIIa mediatedactivity (cf. FIG. 2c ), Example 1), i.e. at least a 2-fold higheractivation of the NFAT pathway than trastuzumab. Trastuzumab exhibits amaximum Fold of induction (FoI) of 26 (cf. FIG. 2a )).

More specifically, the antibody according to the invention may increasethe Fc receptor signaling activity in an FcγRIIIa assay by at least10-fold, preferably at least 20-fold, more preferably at least 50-fold,most preferably 70-fold or more (cf. Example 1, FIG. 2b ) c)).

It is preferred that an antibody according to the invention increasesthe Fc receptor signaling activity in an FcγRIIIa assay by 17-fold,preferably by 22-fold, more preferably by 50-fold and most preferably by70-fold.

The antibodies according to the invention are also more potent ascommercially available antibodies.

In SBKR-3 cells, the antibodies according to the invention, show astimulation of FcR signaling that is preferably more than 100-fold, morepreferably more than 110-fold, 120-fold and more preferably more than130-fold at an EC50 of 52 ng/ml. A preferred antibody may increase FcRsignaling by 132-fold at an EC50 of 52 ng/ml (cf. FIG. 6). This reflectsa much higher signaling potency as Trastuzumab. Trastuzumab exhibits acomparable increase of signaling at an EC50 of 81 ng/ml.

This increased activity in comparison to conventional antibodies used incancer therapy clearly shows its superiority and outstanding potentialfor the use in the treatment of HER2-mediated diseases.

In order to find novel, more effective monoclonal antibodies than thosethat are commercially available and conventionally used in cancertherapy, the inventors selected the most promising candidate antibodiesand tested them in competition assays (Example 2).

Surprisingly, several molecules were found to bind to different epitopesas the gold-standard antibodies for breast cancer therapy, trastuzumab(TZ) and pertuzumab (PZ), i.e. exhibiting a different and unique mode ofaction. In combination with their increased activity in NFAT pathwaystimulation assays (Example 1, FIG. 2), the differential bindingcharacteristic makes them ideal novel reagents for the use in treatingHER2-mediated diseases.

Therefore, the antibody according to the invention binds to a differentepitope than trastuzumab. Preferably, the antibody according to theinvention also bind to a different epitope than pertuzumab.

This means that the antibody according to the invention does not competewith trastuzumab in an epitope competition assay (FIG. 3).

Also preferred is an antibody according that does not compete withpertuzumab in an eptitope competition assay. With the antibodiesdesignated as B106 and B115 being an exception, it is preferred that theantibodies do not compete with pertuzumab in an epitope competitionassay (FIG. 3).

The antibodies according to the invention have the advantage to be verypotent when it comes to binding to their target. They exhibit a strongbinding capacity to their antigen, HER 2, but not to other receptors.The binding properties of the antibodies were studied in biochemicalenzyme-linked immunosorbent assays (ELISA—cf. Example 3 and 4), and areexemplified in FIGS. 4, 5 and 7.

Preferred antibodies according to the invention, show a half maximaleffective concentration (EC50) of less than 8 ng/ml, preferably of morethan 6 ng/ml in experiments as described in Example 3). A preferredantibody, MABD B100, shows an EC50 of 5,2 ng/ml which is comparable tothe EC50 of Trastuzumab and Pertuzumab (cf. FIG. 4).

Strikingly, the antibodies according to the invention also show a verystrong binding to their antigen in experiments in which HER 2 isexpressed in the SK-BR-3 cell line (cf. Example 5). Preferably, theantibodies exhibit an EC50 of less than 100 ng/ml, preferably less than80 ng/ml. A preferred antibody according to the invention, MABD B100,shows an EC50 of 78 ng/ml which is comparable to the EC50 of Trastuzumaband Pertuzumab.

The antibodies according to the invention are also very specific intheir binding properties. The show a strong binding to HER 2, but not tothe homologous receptors HER1, HER3 or HER 4. This is examplied in FIG.7. Strikingly, the inventors found that this is independent of theconcentrations used. All antibodies tested show specific binding to HER2within the concentration range of 1 ng/mL to 2000 ng/mL. Even at aconcentration of more than 100-fold the EC50 of HER2 ELISA, no signal ofbinding to HER1, HER3 and HER4 was detected.

The inventors also found that the antibodies according to the inventiondo not only bind to human HER2, but may also be capable of binding toHER2 orthologues. It is preferred that antibodies according to theinvention show strong binding to human and cynomolgus HER2 receptors.They may show partial binding to rat HER2 receptor. As it is shown inFIG. 7b ), the binding of various antibody according to the invention,to human and cynomolgus HER2 receptors was at a comparable strength,with similar EC50 values and the antibodies tested also showed a partialreactivity for rat HER2 (EC50 >100 ng/mL), but no reactivity to murineHER2.

Surprisingly, and in contrast to commercially available antibodies andantibodies of prior art, the inventors found that the antibodies of thisinvention are capable of inducing apoptosis with an efficacy comparableto a cytotoxic drug like camptothecin. This is an outstanding activitythat will be additive to the activity of other HER2 antibodies withdifferent modes of action. There is no risk for additional toxicities.In contrast to Trastuzumab and Pertuzumab, the antibodies of theinvention are capable of inducing apoptosis in at least 60%, preferablymore than 65%, more than 70%, 75%, 80% and most preferred more than 85%of cells in SK-BR-3 cell line experiments compared to the positivecontrol camptothecin. In one embodiment of the invention, the antibodyshows an induction of apoptosis in 75% of cells, in contrast to only 10%for Trastuzumab and 12% for Pertuzumab (FIG. 8).

As said before, a monoclonal antibody according to the invention can berabbit antibody. Preferably, it is a rabbit/human chimeric antibody. Ina further preferred version, the antibody is a humanized antibody.

The humanized versions of the antibodies according to the inventionmaintain the favorable properties of their chimeric versions. Forexample, they remain their strong binding capacity and potency.Preferred humanized antibodies according to the invention show an EC50of less than 10 ng/ml. In other embodiments, the antibody exhibits an EC50 of less than 9 ng/ml, less than 8 ng/ml, less than 7 ng/ml or lessthan 6 ng/ml, most preferred of 5.3 ng/ml. FIG. 9 shows examples of someof the preferred antibodies of the invention and their potency.

Also, the humanized versions of the antibodies according to theinvention show strong binding capacity in SK-BR-3 experiments (cf. e.g.FIG. 10, Example 4). Preferred humanized antibodies according to theinvention show an EC50 of less than 80 ng/ml. In other embodiments, theantibody exhibits an EC 50 of less than 70 ng/ml, less than 60 ng/ml,less than 50 ng/ml or less than 40 ng/ml. or most preferred, less than20 ng/ml. FIG. 10 shows example of some of the preferred antibodies ofthe invention and their potency.

The humanized antibodies according to the invention are also capable ofinducing strong Fcγ-receptor signaling. Preferably, the Fcy signaling iscomparable to the signaling of the chimeric versions of the antibodiesor more potent. It is also preferred that the induction of Fcy signalingis stronger as for commercially available antibodies. In certainembodiments of the invention, the humanized antibodies have an EC 50 ofless than 300 ng/ml, preferably less than 200 ng/ml, less than 100nt/ml, less than 95 ng/ml and most preferably less than 60 ng/ml.

As noted before, in contrast to commercially available antibodies andantibodies of prior art, the antibodies of this invention are capable ofinducing apoptosis. This holds also true for the humanized version ofthe antibodies. The humanized antibodies of the invention show aninduction of apoptosis of at least 60%, preferably more than 65%, morethan 70%, 75%, 80% and most preferred more than 85% (FIG. 12, Example7).

Strikingly and in contrast to the commercially available antibodies theinventors surprisingly found that the antibodies of the invention arecapable of greatly reducing tumor burden in mice. In a HTM-SK-BR-3 tumormodel, the antibodies according to the invention are capable of reducingthe size of a tumor and the amount of cancer cells dramatically, incontrast to Trastuzumab and Pertuzumab.

Preferred antibodies of the invention can reduce the tumor cell numberby more than 80%, preferably more that 85% and most preferred of morethan 90%, when compared to Trastuzumab. (cf. FIG. 13).

The inventors found a strong anti-tumor and anti-metastatic activity ofthe antibodies according to the invention also when analyzinghistological sections and tumor cell number of different tissues viaflow cytometry. In contrast to commercially available antibodies such asTrastuzumab and Pertuzumab and other antibodies of prior art, theantibodies of the invention strongly reduce tumor cell numbers. Forexample, tumor cell number is reduced in lung, liver and brain tissueafter treatment with said antibodies (cf. FIG. 14a ) and b)).

Furthermore, the antibodies of the invention can efficiently inhibitmetastasis of tumor cells, in contrast to commercially availableantibodies and to other antibodies of prior art. For example, theantibodies can inhibit the dissemination of tumor cells into the bonemarrow in contrast to Trastuzumab and Pertuzumab (FIG. 15).

Due to the specific and favorable properties, the antibodies accordingto the invention are particularly suited in the treatment of a diseasein which the dysregulation of their target antigen is the underlyingreason. Due to these specific properties, they are much better suitedthan commercially available antibodies and other antibodies of priorart.

Therefore, the antibodies according to the invention are especiallyuseful for the treatment of diseases where the dysregulation of the HER2is the underlying reason.

Therefore, the invention also encompasses an antibody according to theinvention for the use in the treatment of a HER-2 mediated disease.

Thus, the present invention also relates to a method of treating anHER-2 mediated disease in a patient, comprising administering to apatient a pharmaceutically effective amount of the antibody according tothe invention.

Moreover, the present invention relates to a pharmaceutical compositioncomprising a pharmaceutically acceptable carrier and a therapeuticallyeffective amount of the antibody according to the invention.

As used herein, “pharmaceutical carrier” includes any and all solvents,dispersion media, coatings, antibacterial and antifungal agents,isotonic and absorption delaying agents, and the like that arephysiologically compatible. Preferably, the carrier is suitable forintravenous, intramuscular, subcutaneous, parenteral, spinal orepidermal administration (e.g. by injection or infusion).

A composition of the present invention can be administered by a varietyof methods known in the art. As will be appreciated by the skilledartisan, the route and/or mode of administration will vary dependingupon the desired results. To administer a compound of the invention bycertain routes of administration, it may be necessary to coat thecompound with, or co-administer the compound with, a material to preventits inactivation. For example, the compound may be administered to asubject in an appropriate carrier, for example, liposomes, or a diluent.Pharmaceutically acceptable diluents include saline and aqueous buffersolutions. Pharmaceutical carriers include sterile aqueous solutions ordispersions and sterile powders for the extemporaneous preparation ofsterile injectable solutions or dispersion. The use of such media andagents for pharmaceutically active substances is known in the art.

The phrases “parenteral administration” and “administered parenterally”as used herein means modes of administration other than enteral andtopical administration, usually by injection, and includes, withoutlimitation, intravenous, intramuscular, intra-arterial, intrathecal,intracapsular, intraorbital, intracardiac, intradermal, intraperitoneal,transtracheal, subcutaneous, subcuticular, intra-articular, subcapsular,subarachnoid, intraspinal, epidural and intrasternal injection andinfusion.

These compositions may also contain adjuvants such as preservatives,wetting agents, emulsifying agents and dispersing agents. Prevention ofpresence of microorganisms may be ensured both by sterilizationprocedures, supra, and by the inclusion of various antibacterial andantifungal agents, for example, paraben, chlorobutanol, phenol, sorbicacid, and the like. It may also be desirable to include isotonic agents,such as sugars, sodium chloride, and the like into the compositions. Inaddition, prolonged absorption of the injectable pharmaceutical form maybe brought about by the inclusion of agents which delay absorption suchas aluminum monostearate and gelatin. Regardless of the route ofadministration selected, the compounds of the present invention, whichmay be used in a suitable hydrated form, and/or the pharmaceuticalcompositions of the present invention, are formulated intopharmaceutically acceptable dosage forms by conventional methods knownto those of skill in the art. Actual dosage levels of the activeingredients in the pharmaceutical compositions of the present inventionmay be varied so as to obtain an amount of the active ingredient whichis effective to achieve the desired therapeutic response for aparticular patient, composition, and mode of administration, withoutbeing toxic to the patient. The selected dosage level will depend upon avariety of pharmacokinetic factors including the activity of theparticular compositions of the present invention employed, the route ofadministration, the time of administration, the rate of excretion of theparticular compound being employed, the duration of the treatment, otherdrugs, compounds and/or materials used in combination with theparticular compositions employed, the age, sex, weight, condition,general health and prior medical history of the patient being treated,and like factors well known in the medical arts.

One aspect of the invention is a pharmaceutical composition according tothe invention for use in the treatment of cancer, as defined in thisapplication.

Another aspect of the invention is a method of treating an HER-2mediated disease in a patient, comprising administering to a patient thepharmaceutical composition according to the invention. Such HER-2mediated diseases may include cancer.

The term “cancer” as used herein may be, for example, lung cancer,non-small cell lung (NSCL) cancer, bronchioloalviolar cell lung cancer,bone cancer, pancreatic cancer, skin cancer, cancer of the head or neck,cutaneous or intraocular melanoma, uterine cancer, ovarian cancer,rectal cancer, cancer of the anal region, stomach cancer, gastriccancer, colon cancer, breast cancer, uterine cancer, carcinoma of thefallopian tubes, carcinoma of the endometrium, carcinoma of the cervix,carcinoma of the vagina, carcinoma of the vulva, Hodgkin's Disease,cancer of the esophagus, cancer of the small intestine, cancer of theendocrine system, cancer of the thyroid gland, cancer of the parathyroidgland, cancer of the adrenal gland, sarcoma of soft tissue, cancer ofthe urethra, cancer of the penis, prostate cancer, cancer of thebladder, cancer of the kidney or ureter, renal cell carcinoma, carcinomaof the renal pelvis, mesothelioma, hepatocellular cancer, biliarycancer, neoplasms of the central nervous system (CNS), spinal axistumors, brain stem glioma, glioblastoma multiforme, astrocytomas,schwanomas, ependymonas, medulloblastomas, meningiomas, squamous cellcarcinomas, pituitary adenoma, lymphoma, lymphocytic leukemia, includingrefractory versions of any of the above cancers, or a combination of oneor more of the above cancers. Preferably such cancer is a breast cancer,colon cancer, lung cancer, or pancreatic cancer. Most preferably thecancer is breast cancer.

EXAMPLES

The following examples are used in conjunction with the figures andtables to illustrate the invention.

Example 1: FcγRIIIa Signaling Assay

The FcγRIIIa signaling assay, which is commercially available e.g. fromPromega, allows for early detection of FcγRIIIa receptor signaling, thusfor effective antibody candidate selection.

Assay Principle:

Target cells (Jurkat), exhibiting the respective antigen (HER2), areincubated with sample antibodies and JIMT-1 cells. The Jurkat cell linestably expresses the FcγRIIIa receptor, V158, possessing a high affinityto human IgG Fc fragment and contains a NFAT-RE-Promotor site, allowingfor the induction of luciferase expression. Upon binding of the antibodyto the target (HER2 expressing) cells, Fc mediated binding of theantibody to the FcγRIIIa receptor, activates the NFAT pathway, thus theexpression of luciferase. Addition of the luciferase substrate(Luciferin), activates a pathway leading to the photoluminescence, whichcan be measured, and correlated qualitatively and semi-quantitatively tothe binding of the antibody to the receptor, i.e. to its immunologicalactivity. Signal strength of Luciferase correlates with the number ofreceptors activated.

Assay Procedure Day 1

-   -   Addition of, for example, 7500 or 15000 JIMT-1 cells in 25 μl        medium, into each well of a microtiter plate.    -   Incubation of cells for 20 to 24 hours at 37° C. and 5% CO2.

Day 2

-   -   Equilibrating of Luciferase Assay buffer and Luciferase        substrate to room temperature.

Manufacture of FcγRIIIa Assay Puffers:

-   -   Thawing of FCS with small amounts of IgG (“low IgG FCS” Hyclone        der Firma Thermo Scientific SH 30898.03) at 37° C. in a water        bath.    -   Addition of the “low IgG FCS” to DMEM cell culture medium (final        concentration: 4%) and    -   Warming up to 37° C. in the water bath.

Concomitant:

-   -   Removal of 23 μl medium from each well with a pipette robot        (CyBi-Well vario, CyBio).    -   Addition of 16 μL sample antibody (diluted in “low IgG FCS”        medium) and 8 μL effector cell-suspension (c=500 000/mL, 4000        cells/well).    -   Incubation for 6 hours, followed by addition of 20 μL        Luciferase-assay-reagent (buffer and Substrat, Promega Corp.)        and incubation for 10 minutes at room temperature.    -   Photometric measurement of luminescence (Tecan infinite M1000        PRO)    -   Substraction of random luminescence, resulting from an        unspecific, spontaneous activation of the NFAT pathway:

FoI=(RLU-sample−RLU-blanc):(RLU-effector−RLU-blank)

Sample: antibody sampleBlanc: blind value (buffer only)Effector: effector cells in medium/buffer without antibodyFoI: signal-to-blanc ratio as x-fold activation (fold of induction)RLU: photometric luminescence (relative luminescence units)

Candidate antibodies were selected in respect to their Fold induction(FoI) of FcγRIIIa activation for the subsequent generation of chimericantibodies. The resulting recombinant antibodies were then tested infollow-up experiments.

Example 2: Epitope Competition Assay Assay Principle

-   -   NUNC Maxisorp 384 well microtiter-plates are coated with        anti-human Fc, which binds to the monoclonal reference antibody.        This plate is designated as “assay plate”.    -   Pre-incubation of the sample antibody with the target antigen        (here: HER2, marked with a His-tag) and with an anti-his        antibody (marked with POD)    -   Addition of the pre-incubation mix to the assay plate.

Materials:

-   Plates: Plate 1: 384 well NUNC Maxisorp plates; Cat. No. 464718    (Assay plate)    -   Plate 2: Pre-incubate plate: PP-Plate either from Axygen or        Deepwell 384 plate-   Coating Ab: Goat Anti-Human IgG (Fc specific); Sigma; Cat. No. I    2136;    -   assay concentration: 0.5 μg/ml-   Proteins: Recombinant Human ErbB2/HER2 Fc Chimera; R&D Systems; Cat.    No. 1129-ER; working conc.: volume dependent (assay conc. 0.3 μg/mL)-   Standard Abs: Herceptin; Roche; Conc: dilution dependent;-   Detection Ab: Monoclonal Anti-polyHistidine Peroxidase Conjugate;    Sigma; Cat. No. A7058; working conc.: volume dependent (see    5.1.1/assay conc. 0.5 μg/mL/e.g. for (90+5+5) μL=20*0.5 μg/mL=6    μg/mL)-   PBS: Buffers in a Box, Premixed PBS Buffer, 10×; Roche Applied    Sciences;    -   Cat. No. 11666789001-   BSA: Bovine Serum Albumin Fraction V from bovine serum;    -   Roche Applied Sciences; Cat. No. 10735086001-   Tween 20: Tween 20; Sigma-Aldrich; Cat. No. P1379-   TMB: TMB Solution; Merck; Cat. No. CLOT-   HCl: 1M Titripur Hydrochloric Acid; Merck; Cat. No. 1090571000-   ELISA Buffer: PBS, 0.5% BSA, 0.05% Tween-   Wash Buffer: PBS, 0.05% Tween-   Block Buffer: PBS, 2% BSA, 0.05% Tween

Assay Procedure

-   1. Coating of NUNC Maxisorp plates with 20 μl goat anti human IgG    (Fc specific) in PBS and incubation for 1 hour at room temperature    (plate1).-   2. 3 washing steps with 90 μl washing buffer per plate-   3. Incubation of the plate for 1 hour at room temperature with 90 μl    blocking buffer-   4. 3 washing steps with 90 μl washing buffer per plate-   5. Incubation of the plate with 20 μl primary antibody (0.2 μg/ml)    in ELISA buffer for 1 h at RT. Concomitant manufacture of the    pre-incubation mix in a different plate (plate 2): Mixing of 90 μl    of the sample antibody in ELISA buffer (working concentration: >2    μg/ml; same concentration for the control antibody), respectively    only ELISA buffer (blank) with 5 μl of protein with HIS-tag (e.g.    HER2-HIS-tag). Addition of 5 ml anti HIS POD-antibody and incubation    of the mix for 1 h at room temperature.-   6. 3× washing of plate with primary antibody with 90 μl washing    buffer.-   7. Addition of 20 μl of the pre-incubation mix from plate 2 into the    wells of plate 1 and incubation for 1 h at room temperature-   8. 6× washing with washing buffer-   9. Addition of 25 μl TMB to each of the wells.-   10. After sufficient color development, stopping of the reaction by    25 μl HCl.-   11. Measurement of the absorption at 450 nm/620 nm.

Example 3: HER 2 Biochemical ELISA (protocol 1) Materials:

-   Plates: 384 well NUNC Maxisorp plates; NUNC; Cat. No. 464718-   Coating Proteins:    -   human Her1 (Recombinant Human EGFR/ErbB1 Fc Chimera; R&D        Systems; Cat. No. 344-ER)    -   human Her2 (Recombinant Human ErbB2/HER2 Fc Chimera; R&D        Systems; Cat. No. 1129-ER)    -   human Her3 (Recombinant Human ErbB3/Her3 Fc Chimera; R&D        Systems; Cat. No. 348-RB)    -   human Her4 (Recombinant Human ErbB4/HER4 Fc Chimera; R&D        Systems; Cat. No. 1131-ER)    -   cyno Her2 (Cynomolgus HER2/ErbB2 Protein; Sino Biological; Cat.        No. 90295-C08H)    -   rat Her2 (Rat HER2/ErbB2 Protein; Sino Biological; Cat. No.        80079-RCCH) mouse Her2 (Mouse Her2/ErbB2 Protein; Acro        Biosystems; Cat. No. ER2-M5220)-   Primary Abs: Trastuzumab    -   Pertuzumab    -   MABD B100    -   MAB-16-0160    -   MAB-16-0161    -   MAB-16-0163    -   MAB-16-0165-   Detection Ab: anti-human Fab2 POD-Antibody; AbD Serotec; STAR126P-   PBS: Buffers in a Box, Premixed PBS Buffer, 10×; Roche Applied    Sciences; Cat. No. 11666789001-   BSA: Bovine Serum Albumin Fraction V from bovine serum; Roche    Applied Sciences; Cat. No. 10735086001-   Tween 20: Tween 20; Sigma-Aldrich; Cat. No. P1379-   TMB: TMB Solution; Invitrogen; Cat. No. SB02-   HCl: 1M Titripur Hydrochloric Acid; Merck; Cat. No. 1090571000-   ELISA Buffer:PBS, 0.5% BSA, 0.05% Tween-   Wash Buffer: PBS, 0.1% Tween-   Block Buffer: PBS, 2% BSA, 0.05% Tween-   Samples: Dilution in ELISA buffer is project dependent (for high    concentrated IgGs 1:2 dilution is recommended)

Procedure:

-   1. Dilute desired coating protein to 0.5 μg/mL in PBS and add 12.5    μL to a 384 well NUNC Maxisorp plate.-   2. Incubate for 1 h at room temperature.-   3. Wash 3× with Wash Buffer.-   4. Add 90 μL Block buffer to each well and incubate for 1 h at room    temperature.-   5. Wash 3× with Wash Buffer.-   6. Add 12.5 μL of the desired primary antibody diluted in ELISA    buffer to the desired concentration.-   7. Incubate for 1 h at room temperature.-   8. Wash 3× with Wash Buffer.-   9. Add 12.5 μL of detection antibody diluted 1:5000 in Elisa Buffer,    and incubate for 1 h at room temperature.-   10. Wash 6× with Wash Buffer.-   11. Add 15 μL TMB.-   12. Add 15 μL HCl after sufficient development time.-   13. Read absorbance at 450 nm/620 nm.-   14. Analyze data with Excel Fit (Fit Model: 205, Pre-Fit for all 4    parameters, no Constrains on any parameter, EC₅₀=parameter C)

Example 4: Cell Binding to SK-BR-3 (Protocol 2) Materials:

-   Cell culture plates: Black, 384we11, clear and flat bottom Corning    Cell culture plates; Corning; Cat. No. 3764-   Cells: SK-BR-3; ATCC; Cat. No. HTB-30-   Primary Ab: Trastuzumab    -   Pertuzumab    -   MABD B100    -   MAB-16-0160    -   MAB-16-0161    -   MAB-16-0163    -   MAB-16-0165-   Detection Ab: AF488-conj. AffiniPure a-HuIgG(H&L) Fragm. Speci.;    Dianova; Cat. No.109-546-003-   Fluorescent dye: Hoechst; Invitrogen; Cat. No. H3570-   FCS: HyClone Fetal Bovine Serum defined; Thermo Scientific; Cat. No.    SH 30070.03-   Cell medium: Mc Coy's with stab. Glutamine, with 2,2 g/1 NaHCO3; PAN    Biotech; Cat. No. P04-06500+10% FCS-   PBS: Buffers in a Box, Premixed PBS Buffer, 10×; Roche Applied    Sciences; Cat. No. 11666789001-   Tween 20: Tween 20; Sigma-Aldrich; Cat. No. P1379-   Cell wash buffer: PBS, 0.05% Tween

Procedure:

-   1. In a cell culture plate, add 20 μL of primary antibody diluted in    cell medium to the desired concentration/-s.-   2. In the same wells, seed cells (1.000 cells/well) in 20 μL cell    medium.-   3. Incubate for 4 h or overnight at 37° C. and 5% CO2.-   4. Wash three times with 750 cell wash buffer.-   5. Dilute detection antibody in cell medium to a concentration of    250ng/mL and add 20 μl to the tested wells.-   6. Incubate for 4 h at 37° C. and 5% CO2.-   7. Dilute the fluorescent dye in cell medium to a concentration of    22.5 μg/mL, and add 5 μl to the tested wells.-   8. Incubate for 10 min-1 h at room temperature.-   9. Analyze binding of antibodies to cells with a Celllnsight™ High    Content Screening Platform (Min. Objects per Well: 250 cells)-   10. Analyze data with Excel Fit (Fit Model: 205, Pre-Fit for all 4    parameters, no Constrains on any parameter, EC₅₀: parameter C)

Example 5: Fcy-Receptor Signaling (Protocol 3) Materials:

-   Plates: White flat-bottom 384-well assay plates with lid; Corning;    Cat. No. 3570-   Target cells: SKBR-3; ATCC; Cat. No. HTB-30-   Effector cells: ADCC Bioassay Effector cells; Promega; Cat. No.    G7011-   Standard mAb: Trastuzumab    -   Pertuzumab    -   MABD B100    -   MAB-16-0160    -   MAB-16-0161    -   MAB-16-0163    -   MAB-16-0165-   ADCC assay buffer: RPMI 1640 Medium & low IgG serum; Promega; Cat.    No. G7010-   FCS: HyClone Fetal Bovine Serum defined; Thermo Scientific; Cat. No.    SH 30070.03-   Target cell medium: Mc Coy's with stab. Glutamine, with 2.2 g/l    NaHCO3; PAN Biotech; Cat. No. P04-06500+10% FCS-   Luciferase assay reagent: BioGlo™ Luciferase Assay Buffer & BioGlo™    Luciferase Assay Substrate; Promega; Cat. No. G7010

Procedure:

-   Day 1:    -   1. Seed target cells: 2500 cells /well in 25 μL target cell        medium    -   2. Incubate for 20-24 h, 37° C., 5% CO2.-   Day 2:    -   3. Prepare Luciferase assay reagent according to manufacturer's        instructions.    -   4. Prepare ADCC assay buffer according to manufacturer's        instructions.    -   5. Remove 23 μL media from all wells of assay plates. Add gently        8 μL of pre-warmed ADCC assay buffer per well to the plate.    -   6. Dilute desired primary antibodies in ADCC assay buffer to the        desired concentrations, and add 8 μL of the antibody dilutions        to wells. As blank add ADCC assay buffer. Store plates on bench.    -   7. Thaw effector Cells in water bath 37° C. (13×10⁶cells/vial;        do not invert).    -   8. Gently mix cells by pipetting. Add 630 μL of cell suspension        to 24.57 mL of pre-warmed ADCC assay buffer.    -   9. Add 8 μL of effector cell suspension per well to the plate        (4000 cells/well).    -   10. Cover plates and incubate for 6 h at 37° C., 5% CO2.    -   11. Remove plates from incubator and equilibrate to room        temperature (15 min).    -   12. Add 20 μL of Luciferase assay reagent to all wells in test.    -   13. Incubate at room temperature for 5-30 min.    -   14. Measure luminescence using a plate reader and calculate        results according to BioGlo™ assay manufacturer's instructions.    -   15. Analyze data with Excel Fit (Fit Model: 205, Pre-Fit for all        4 parameters, no Constrains on any parameter, EC50: parameter C)

Example 6: Apoptosis Assay (Protocol 5) Materials:

-   Cell culture plates: 6-well cell culture plates, Nunclon surface;    Nunc; Cat. No.: 140685-   Assay plates: 96- DWP DNA LoBind plates; Eppendorf; Cat. No.:    0030602.307-   Cells: SKBR-3; ATCC; Cat. No. HTB-30-   FCS Fetal Bovine Serum South Africa Low IgG (PAN; Cat. No.    1552-P120909)-   Cell- and Assay-Medium: DMEM; PAN; Cat.-No.: PO4-04510+5% FCS-   Primary Ab: Pertuzumab    -   Trastuzumab    -   MABD B100    -   MAB-16-0160    -   MAB-16-0161    -   MAB-16-0163    -   MAB-16-0165-   Reagents: (A) Annexin V FITC-conjugated; Immunotools; Cat. No.:    31490013X2    -   (C) Camptothecin; Sigma-Aldrich; Cat. No.: C9911    -   (D) DRAQ7™; Abcam; Cat. No.: ab109202-   Binding buffer: 0,1M HEPES; Gibco; Cat. No.: 15630-106+1.4M NaCl;    Sigma; Cat. No.: S7653-1kg+25mM CaCl2; Fluka; Cat. No.: 21114-1L

Protocol:

-   1. Seed cells (8×10⁴ cells/well) in 2 mL cell medium per well of    cell culture plates. Incubate 72 h; 37° C.; 5% CO2.-   2. Remove medium.-   3. Add to plate, 2 mL assay-medium (control wells) or primary    antibody diluted to desired concentration in assay-medium.-   4. Incubate 48 h; 37° C.; 5% CO2.-   5. Add 50 Camptothecin (2 mM) to one or more wells as positive    control.-   6. Incubate 24 h; 37° C.; 5% CO2.-   7. Transfer supernatant from each well to a separate 15 ml-tube-   8. Wash each well with 1.5 ml PBS and transfer supernatant to its    same respective 15 ml-tube.-   9. Add 0.5 ml Trypsin to each well, incubate at 37° C., then stop    with 1.5 ml cell-medium and transfer all liquid to its respective 15    ml-tube.-   10. Add 5 ml PBS to each 15 ml-tube.-   11. Centrifuge 15 ml-tubes at 300 g, 3 min, 4° C., and discard    supernatant-   12. Add 140 μL precooled Binding Buffer (4° C.), re-suspend and    transfer 70 μL to assay plates.-   13. Add 5 μL precooled Annexin (4° C.), mix and incubate 20 min on    ice/dark.-   14. Add 2 μL DRAQ7™ diluted 1:100 in binding buffer.-   15. Add 120 μL precooled binding buffer (4° C.), mix and incubate    7min on ice/dark. Perform flow cytometry analysis.

FIGURE LEGEND

FIG. 1: Sequences (amino acids in one letter code)

Complete sequences of Variable Regions (VR):

Heavy chain: VH complete: SEQ ID NO: 1-6 and SEQ ID NO: 100-101 Lightchain: VL complete: SEQ ID NO: 7-12 and SEQ ID NO: 102-104

The VL sequences may comprise a Cysteine to Serine mutation at position90.

Complementary Determining Regions (CDR):

Heavy Chain: CDR-H1: SEQ ID NO: 13-18 CDR-H2: SEQ ID NO: 19-24 CDR-H3:SEQ ID NO: 25-30 Light Chain: CDR-L1: SEQ ID NO: 31-36 CDR-L2: SEQ IDNO: 37-42 CDR-L3: SEQ ID NO: 43-48

Framework Regions (FR):

Heavy Chain: FR-H1: SEQ ID NO: 49-54 FR-H2: SEQ ID NO: 55-60 FR-H3: SEQID NO: 61-66 FR-H4: SEQ ID NO: 67-72 Light Chain: FR-L1: SEQ ID NO:73-78 FR-L2: SEQ ID NO: 79-84 FR-L3: SEQ ID NO: 85-90 FR-L4: SEQ ID NO:91-96

Constant Regions (CR):

Light Chain: CR-L: SEQ ID NO: 97 Heavy Chain: CR-H: SEQ ID NO: 98-99

FIG. 2: Antibody selection through FcγRIIIa signaling assay

Details of the assay procedure are disclosed in example 1. Candidateantibodies were selected in respect to their Fold of Induction (FoI) ofFcγRIIIa signaling.

-   a) FoI of FcγRIIIa signaling by trastuzumab, in dependence of the    antibody concentration. The maximum FoI is approximately 26.-   b) FoI of FcγRIIIa signaling by a selected candidate antibody. The    maximum FoI is >75.-   c) Candidate antibodies were selected according to their FoI to    produce recombinant chimeric antibodies. Shown are FcγRIIIa    signaling results of the chimeric antibodies in follow-up    experiments.

FIG. 3: Epitope competition assay

None of the selected antibodies according to the invention compete withtrastuzumab for its epitope, while Herceptin (positive control) reducesthe POD signal by over 80% (+++). As positive control, the presence ofpertuzumab in the pre-incubation mix reduces the POD signal over 80%(+++) in a concentration dependent manner. B106 shows epitopecompetition with pertuzumab, while B115 shows partial competition forthe pertuzumab epitope. No epitope competition is observed with anyother of the selected candidate antibodies according to the invention.

FIG. 4: HER2 biochemical ELISA

The results shown were obtained in experiments as described in Example3.

A preferred antibody according to the invention, MABD B100, shows anEC50 of 5.2 ng/ml which is comparable to the EC50 of Trastuzumab andPertuzumab.

FIG. 5: Binding to SK-BR-3 cell line

The results shown are from experiments as described in Example 4.

A preferred antibody according to the invention, MABD B100, shows anEC50 of 78 ng/ml which is comparable to the EC50 of Trastuzumab andPertuzumab.

FIG. 6: Fcγ-receptor signaling

The results shown were obtained in experiments as described in Example5.

A preferred antibody according to the invention, MABD B100, shows astimulation of FcR signaling of 132-fold at an EC50 of 52 ng/ml.Trastuzumab exhibits a comparable signaling strength at an EC 50 of 81ng/ml. This highlights the improvement in potency over commerciallyavailable antibodies.

FIG. 7: Receptors binding in ELISA experiments

Antibody binding to different receptors was tested in biochemical ELISAexperiments. The experiments were carried out according to the protocolas detailed in Example 3 (Protocol 1).

a) Binding to Homologues HER Receptors

All tested antibodies show specific binding to HER2 within theconcentration range of 1 ng/mL to 2000 ng/mL. Even at a concentration ofmore than 100-fold the EC₅₀ of HER2 ELISA, no signal of binding to HER1,HERS and HER4 was detected.

b) Binding to Orthologues of HER2

The binding of antibody according to the invention, to human andcynomolgus HER2 receptors was comparable, with similar EC₅₀ values. Theantibodies showed a partial reactivity for rat HER2 (EC₅₀>100 ng/mL),but no reactivity to murine HER2.

FIG. 8: Apoptosis induction on SK-BR-3 cell line

FIG. 8 shows the results of experiments that were carried out accordingto the protocol of Example 7. Apoptosis induction was measured asAnnexin staining after in-vitro incubation. Camptothecin was used aspositive control (set as 100%). MABD B100 shows a uniquely strongapoptosis induction (75%), in contrast to Trastuzumab (10%) andPertuzumab (12%).

FIG. 9: HER2 biochemical ELISA of humanized variants

Shown are the results of experiments that were carried out according toExample 3.

Four preferred humanized monoclonal antibody candidates maintain thefavorable in vitro properties of the chimeric version.

FIG. 10: Binding to SK-BR-3 cell line of humanized Mab variants

Experiments were carried out according to the protocol as described inExample 4.

The four humanized leads maintain in vitro properties of the chimericversion.

FIG. 11: Fcγ-receptor signaling of humanized Mab variants

Experiments were carried out according to the protocol as described inExample 5. The four humanized leads maintain in vitro properties of thechimeric version.

FIG. 12: Apoptosis induction of humanized Mab variants

Experiments were carried out according to the Protocol as described inExample 7. Camptothecin (second row) was used as positive control (setas 100%). The preferred humanized antibodies according to the inventionshow a strikingly strong apoptosis induction (68% to 83%).

FIG. 13-15: In vivo experiments

In vivo experiments were carried out in well-established humantransplant mouse models (HTM) (Wege et al. 2011/2014/2016).Specifically, the HTM model with the SK-BR-3 tumor cell line wasemployed. This model is resistant to trastuzumab treatment and showsstrong dissemination and metastasis. The experiments comprised 9 weeksof establishment of immune system, tumor and metastases and 12 weeks oftreatment with 5 mg/kg/week i.p. antibody or placebo.

FIG. 13: In vivo Profile of MABD B100: Tumor burden after treatment

Animals with a functional human immune system were analyzed at the endof treatment.

Treatment with a preferred antibody according to the invention, MABDB100, resulted in a strong reduction of tumor burden compared totreatment with the control, trastuzumab and pertuzumab antibodies.

Remission (4/5) or >95% reduction (⅕) by MABD B100 treatment: p=0.037vs. control

No effect with trastuzumab and pertuzumab treatment: not significant

FIG. 14: In vivo Profile of MABD B100: Anti-Tumor and Anti-MetastaticActivity

Experiments were carried out in the HTM-SK-BR-3 model and results wereevaluated qualitatively (Y/N): Metastases by IHC (a) and by flowcytometry (b)

-   a) HER2+ Tumor cells in histological sections-   b) HER2+ tumor cells analyzed by flow cytometry-   Column 2: Control: Animals with a functional human immune system at    the end of treatment-   Column 3: Treatment with Trastuzumab-   Column 4: Treatment with the MABD B100-   Column 5: Treatment with Pertuzumab-   Colum 6+7: Historical data included from Wege et al. 2016

FIG. 15: In vivo Profile of MABD B100: Dissemination of Tumor Cells toBone Marrow

Experiments were carried out in the HTM-SK-BR-3 model and results wereevaluated qualitatively (Y/N). Cells were isolated from bone marrow andcultivated. After expansion, cells were tested for resistance totreatment by FACS.

Control: Animals with a functional human immune system at the end oftreatment.

MABD B100 shows an efficient inhibition of dissemination of tumor cellsto the bone marrow.

1.-21. (canceled)
 22. A monoclonal antibody that specifically binds toHER2, or a fragment or derivative thereof or a polypeptide that containsat least a portion of said antibody that is sufficient to confer HER2binding specificity, and is at least 2-fold more effective in inducingapoptosis in cells of a cancer cell line than trastuzumab or pertuzumab.23. The antibody according to claim 22, wherein the antibody is at least3-fold more effective in inducing apoptosis in the cells thantrastuzumab or pertuzumab.
 24. The antibody according to claim 23,wherein the antibody is at least 4-fold more effective in inducingapoptosis in the cells than trastuzumab or pertuzumab.
 25. The antibodyaccording to claim 22, wherein the antibody induces apoptosis in atleast 60% of the cells.
 26. The antibody according to claim 25, whereinthe antibody induces apoptosis in at least 75% of the cells.
 27. Theantibody according to claim 22, wherein the EC50 of the antibody is lessthan the EC50 of trastuzumab.
 28. The antibody according to claim 27,wherein the EC50 of the antibody is less 80 ng/ml.
 29. The antibodyaccording to claim 22, wherein said antibody also binds to the human Fcreceptor and induces FcR mediated signaling pathways.
 30. The antibodyaccording to claim 29, wherein said antibody increases the Fc receptorsignaling activity in an FcγRIIIa assay by at least 10-fold.
 31. Theantibody according to claim 29, wherein said antibody binds to adifferent epitope than trastuzumab.
 32. The antibody according to claim29, wherein said antibody does not compete with trastuzumab in anepitope competition assay.
 33. The antibody according to claim 29,wherein said antibody does not compete with pertuzumab in an epitopecompetition assay, except for the antibodies designated as B106 andB115.
 34. The antibody according to claim 22, wherein said antibody iscapable of reducing the tumor burden, tumor dissemination andmetastasis.
 35. A method of treatment of a HER-2 mediated diseasecomprising administering to a subject in need thereof an effectiveamount of the antibody according to claim 1 to treat a HER-2 mediateddisease.
 36. A pharmaceutical composition comprising a pharmaceuticallyacceptable carrier and a therapeutically effective amount of theantibody according to claim
 22. 37. The antibody according to claim 22,wherein the antibody comprises a heavy chain variable (VH) region thatis at least 90% identical to the VH region of SEQ ID NO: 4 and a lightchain variable (VL) region that is at least 90% identical to the VLregion of SEQ ID NO:
 10. 38. The antibody according to claim 22, whereinthe antibody is a humanized antibody.
 39. The antibody according toclaim 22, wherein the antibody comprises a VH region selected from thegroup of VH regions comprising a CDR-H1 region of SEQ ID NO: 13+n, aCDR-H2 region of SEQ ID NO: 19+n and a CDR-H3 region of SEQ ID NO: 25+n,wherein n is a number selected from the group consisting of 0 to
 5. 40.The antibody according to claim 22, wherein said antibody comprises a VLregion selected from the group of VL regions comprising a CDR-L1 regionof SEQ ID NO: 31+n, a CDR-L2 region of SEQ ID NO: 37+n and a CDR-L3region of SEQ ID NO: 43+n, wherein n is a number selected from the groupconsisting of 0 to
 5. 41. The antibody according to claim 22, whereinthe antibody comprises: a) a heavy chain variable (VH) region is atleast 90% identical to a VH region selected from the group consisting ofVH regions of SEQ ID NO: 1 to 6 and SEQ ID NO: 100 to 101, and b) alight chain variable (VL) region at least 90% identical to a VL regionselected from the group consisting of VL regions of SEQ ID NO: 7 to 12and SEQ ID NO 102 to 104.